about
sameAs
A sensitive method for detecting variation in copy numbers of duplicated genes.Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urinePrecision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite RatioBarriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians.Contribution of environment and genetics to pancreatic cancer susceptibilityPhenotypic CYP2A6 variation and the risk of pancreatic cancer.Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.CYP2A6 Polymorphisms May Strengthen Individualized Treatment for Nicotine Dependence.Identification of Ethanol and 4-Nitroquinoline-1-Oxide Induced Epigenetic and Oxidative Stress Markers During Oral Cavity CarcinogenesisCohort Profile: The Nicotine Dependence in Teens (NDIT) Study.Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: potential breast cancer risk alleles and their distribution across human populations.Predictors of cessation in African American light smokers enrolled in a bupropion clinical trialGenetics of tobacco use.Inter-individual Variability of Coumarin 7-hydroxylation (CYP2A6 activity) in an Iranian PopulationCYP2A6 polymorphisms and risk for tobacco-related cancers.Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro.Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.Role of cytochrome P-450 genetic polymorphisms in oral carcinogenesis.A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity.The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians.Genetics of Tobacco Use.Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach.Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation?Cytochrome p450 metabolism of betel quid-derived compounds: implications for the development of prevention strategies for oral and pharyngeal cancers.Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer.Point mutation of cytochrome P450 2A6 (a polymorphic variant CYP2A6.25) confers new substrate specificity towards flavonoids.Molecular Determinants of Substrate Affinity and Enzyme Activity of a Cytochrome P450 Variant
P2860
Q33679715-12082B0E-37C3-4815-9A45-BEAC6EA24E14Q33768433-518C042A-72B6-430F-800C-8E17A346B6C1Q33821233-53B8BE36-FE99-4B61-9775-023952D2315DQ34722733-7ADC6478-C701-4054-B9E1-6966CF9C4056Q35126601-A87EBC97-2389-4275-9373-2005BA68388FQ35428436-C7F2D9EC-C94F-4CE8-B98B-358CAFFFE289Q35539136-C66D67AB-125D-40BC-8397-D930D0E70B40Q35594492-D01CC13E-FA6B-4A32-BF77-6183ECB265E1Q36135652-AFB80540-C891-4550-ADC0-FE13CC12918CQ36376677-51B5D5F2-EEE2-4FD5-BFA3-DDAD0923BE29Q36405312-AB31B2B6-1CA1-4458-B324-0023624453A9Q36572648-43185C2C-2048-4FE0-A738-70B0B918DB93Q37164984-FBDDD736-6A6F-4915-8592-900ED4CF1182Q37292058-D133C491-F232-4163-92A5-2C829CE1F3AAQ37329175-6DF6C03A-CAB6-4882-A263-FA6302B0BD74Q37414581-AE8E15A6-489E-414C-88D6-B04778CE2F1CQ37745041-536FAEDF-5457-42D9-9F34-74B25B030446Q37906754-3D164E69-B9E8-4B6B-9267-DF42C90F5417Q38772466-17685E5D-B54F-408E-9FFC-283D978C3A46Q43093974-A03F663E-A8AD-4387-85A5-CB3EDC7BA282Q44344781-877F8FFF-3EA7-4EC2-92A8-45F0CFB26A51Q45144875-EEB9FC90-78C3-4B79-B002-59B3936BCFEAQ46660426-F3C4DFA6-73CA-4610-94EA-5840C42014E6Q46886466-B1FED74B-96F8-46C7-BA9A-99180A378A46Q46960266-02099A11-5746-4793-98E9-0BE3563CB980Q48158115-986319A8-62F8-472F-A2B0-F0E1523249DBQ51370536-197904A9-CEF2-4327-B650-7244175B4C85Q52306926-08716DF1-0BDA-486D-ACF0-112DB470E1A3Q54263454-F2A0205F-DCD2-48D6-8747-66D95E99911BQ57044266-5442BB98-620F-4C83-8435-574B82F4D758
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
CYP2A6 genetic variation and potential consequences
@ast
CYP2A6 genetic variation and potential consequences
@en
CYP2A6 genetic variation and potential consequences
@nl
type
label
CYP2A6 genetic variation and potential consequences
@ast
CYP2A6 genetic variation and potential consequences
@en
CYP2A6 genetic variation and potential consequences
@nl
prefLabel
CYP2A6 genetic variation and potential consequences
@ast
CYP2A6 genetic variation and potential consequences
@en
CYP2A6 genetic variation and potential consequences
@nl
P1476
CYP2A6 genetic variation and potential consequences
@en
P2093
P304
P356
10.1016/S0169-409X(02)00065-0
P407
P577
2002-11-01T00:00:00Z